Physician profile
Pedram Navid
NPI 1245727247
$1,619.76
in general payments reported to CMS, 2019-2025
11 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $12.10 · 2023: $394 · 2024: $643 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $357.59 | 2023-2024 | Lifevest |
| Medtronic, INC. | $298.86 | 2021-2025 | Affera Mapping System |
| Edwards Lifesciences Corporation | $220.28 | 2024 | Sapien 3 Ultra Resilia |
| Abiomed | $172.82 | 2023 | Impella |
| Boston Scientific Corporation | $169.37 | 2024 | Watchman Flx |
| Shockwave Medical, INC | $143.91 | 2025 | |
| Heartflow, INC. | $85.89 | 2025 | |
| Pfizer INC. | $80.89 | 2021-2023 | |
| Biosense Webster, INC. | $50.00 | 2024 | Carto 3 |
| Abbott Laboratories | $23.76 | 2024 | Aveir |
| Amgen INC. | $16.39 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedram Navid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.